Affimed Reports New Data for AFM13 from Two Separate Clinical Trials in Hodgkin and CD30-Positive Lymphomas

Biotech Investing

Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today reported additional preliminary patient data from two separate clinical studies of its lead NK cell engager candidate AFM13. As quoted in the press release: “We are extremely encouraged by these new data which indicate that the …

As quoted in the press release:

“We are extremely encouraged by these new data which indicate that the first-in-class NK cell engager AFM13 has achieved clinically meaningful responses both as single agent and in combination with a checkpoint inhibitor” said Dr. Adi Hoess, CEO of Affimed. “In particular, in our combination trial with Keytruda, we are excited to have increased both overall and complete metabolic response rates.”

Click here to read the full press release.

affimed cancer clinical studies clinical-stage biopharmaceutical clinical-stage biopharmaceutical company keytruda patient Biotech Investing